title: Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.
authors.affiliation: a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Fréderic
authors.initials: F
authors.lastname: Franconieri
authors.affiliation: a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Martin-Silva
authors.affiliation: a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Hubert
authors.initials: H
authors.lastname: de Boysson
authors.affiliation: b Department of Pathology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Galateau-Salle
authors.affiliation: c Department of Pathology , CHU Ambroise Paré , Boulogne , France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Emile
authors.affiliation: a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Boris
authors.initials: B
authors.lastname: Bienvenu
authors.affiliation: a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
authors.forename: Achille
authors.initials: A
authors.lastname: Aouba
mesh_terms: D000368:Aged; D031249:Erdheim-Chester Disease / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D005260:Female; D060831:Hand-Foot Syndrome / Q000209:etiology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D053590:Interleukin 1 Receptor Antagonist Protein; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf